Niraparib-TSR-042
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Niraparib-TSR-042, covering 2021-08-27 to 2021-08-27. Get the full timeline:
Most recent: Clinical Trial Update: Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment [Phase 3]